23 March 2021

Download as PDF

tranScrip is delighted to announce the appointment of Louise Rowe as a Senior Partner. 

Louise brings 30 years of global experience working in all phases of cross-functional drug development, from proof-of-concept to reimbursed market access and lifecycle management, including Rx to OTC switch.

Strengths include team leadership and creative problem-solving through a collaborative approach to cross-functional drug development, in particular, building high performing teams and synthesising integrated project plans that deliver the target product profile on time and within budget.

Louise enjoys engaging in late-stage programs, preparing for the transition from development to commercialisation, whilst simultaneously navigating the regulatory landscape to achieve successful marketing authorisations.

Louise joined tranScrip from Orchard Therapeutics, where she was VP, Program Lead for LibmeldyTM, the first gene therapy for treatment of a rare neurometabolic disorder, metachromatic leukodystrophy. She successfully led the Program Team from the time of asset acquisition through to European Marketing Authorisation.

In her role as a Program Director at Novartis, Louise built high-performing cross-functional teams developing assets across a broad range of indications including Urology, Nephrology, Osteoporosis and Rheumatology/ Immunology for global markets including Japan and China.

Prior to joining Novartis, Louise worked in Clinical Research for 10 years, in pharma companies and CROs, delivering studies in pain, GI, urology, women’s health and CNS.

Flic Gabbay, tranScrip’s Managing Partner said, “I am particularly pleased to welcome Louise into tranScrip at this moment in time as we go through a significant investment and growth phase. Her project leadership skills will be invaluable as our teams grow to cover the many aspects of the drug development licensing and launch for our many clients.”